Why did Artivion (AORT) stock move recently?

On 7/28/2026, Artivion moved +3.5% — No specific company catalyst identified in today's coverage; the gain appears to reflect broader market or sector momentum following recent FDA approval and institutional buying news. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Artivion (AORT) overvalued or fairly valued?

MarketChacha shows Artivion's valuation in context — a forward P/E of about 32.7, a price-to-book of about 2.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Artivion's revenue?

Artivion reported revenue of $441.3M for FY2025, with net profit of $9.8M, per official filings.

What is the share price of Artivion (AORT)?

Artivion last traded at $25.57 (-0.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Artivion

AORT · NYSE · Healthcare · United States

Snapshot

TickerAORT

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees1,800

HeadquartersKennesaw, United States

Websiteartivion.com

Filings tracked15

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Who owns it

Insiders4.3%
Institutions95.7%
Public & other0.0%

290 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.13.69%
Nomura Asset Management International Inc6.53%
Morgan Stanley5.25%
Juniper Investment Company, LLC4.14%
Vanguard Capital Management LLC4.11%
FMR, LLC4.03%
State Street Corporation3.81%
Ophir Asset Management Pty Ltd3.69%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 2.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-8.7% → 2.2%

Margin has expanded by about 10.9 points — the business is getting more profitable.

Return on equity2.2%

Latest ROE of 2.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $128.7M · EPS 0.15

Est. earnings growth -13.7%

Next fiscal year

Rev $543.2M · EPS 0.78

Est. earnings growth +77.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$441.3M

Net margin

2.2%

ROE

2.2%

Revenue CAGR (2y)

+11.7%

EPS (FY2025)

0.21

Net profit (FY2025)

$9.8M

Ask MarketChacha about AORT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
No specific company catalyst identified in today's coverage; the gain appears to reflect broader market or sector momentum following recent FDA approval and institutional buying news.
· confidence: low
Jul 27, 2026
No company-specific news or filing on July 27; the move appears to lack a clear catalyst and occurred alongside broader market/sector trading.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$441.3M	$9.8M	0.21	2.2%	2.2%
FY2024	$388.5M	$-13.4M	-0.32	-3.4%	-4.8%
FY2023	$354.0M	$-30.7M	-0.75	-8.7%	-10.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$125.8M	$-13.5M	-0.28	-10.7%
2026Q1	$116.3M	$1.4M	0.03	1.2%
2025Q3	$113.4M	$6.5M	0.13	5.7%
2025Q2	$113.0M	$1.3M	0.03	1.2%
2025Q1	$99.0M	$-505,000	-0.01	-0.5%
2024Q3	$95.8M	$-2.3M	-0.05	-2.4%
2024Q2	$98.0M	$-2.1M	-0.05	-2.2%
2024Q1	$97.4M	$7.5M	0.18	7.7%
2023Q3	$87.9M	$-9.8M	-0.24	-11.2%
2023Q2	$89.3M	$-3.4M	-0.08	-3.8%
2023Q1	$83.2M	$-13.5M	-0.33	-16.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/7/2026
8-K — Results of operations, Exhibits
SEC8/6/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC5/18/2026material
8-K — Shareholder vote results
SEC5/15/2026material
10-Q filing
SEC5/8/2026
8-K — Material agreement, Results of operations, Exhibits
SEC5/7/2026material
10-K filing
SEC2/18/2026
8-K — Results of operations, Exhibits
SEC2/12/2026material

2025

10-Q filing
SEC11/7/2025
8-K — Results of operations, Exhibits
SEC11/6/2025material
8-K — Material agreement, Exhibits
SEC9/29/2025material
8-K — Material agreement, Material financial obligation, Exhibits
SEC9/15/2025material
8-K — Executive/director change
SEC8/11/2025material
10-Q filing
SEC8/8/2025
8-K — Results of operations, Exhibits
SEC8/7/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.